Regeneron Pharmaceuticals Inc

REGNNASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
594.54 USD
↘ 6.12 (1.02%)🟢PRE MARKET (AS OF 05:58 AM EDT)
🟢Market: OPEN
Open?$600.75
High?$600.75
Low?$594.54
Prev. Close?$600.66
Volume?394
Avg. Volume?1.0M
VWAP?$599.20
Rel. Volume?0.00x
Bid / Ask
Bid?$576.62 × 40
Ask?$640.50 × 40
Spread?$63.88
Midpoint?$608.56
Valuation & Ratios
Market Cap?63.0B
Shares Out?103.0M
Float?98.3M
Float %?94.6%
P/E Ratio?14.24
P/B Ratio?2.00
EPS?$42.19
Dividend?0.59%
Ex-Dividend?N/A

Regeneron Pharmaceuticals Inc (REGN) trades at $594.54 per share. The technical outlook is "Strong Sell" and the fundamental picture shows "Neutral". Key drivers include a robust Altman Z-Score and a bullish Golden Cross on the moving averages. On the valuation side, REGN appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Jun 1, 2026.

News
Profile
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Themes
Biotech - Drug Development›Immunology & AutoimmuneHealthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
15.4K
Market Cap
64.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.regeneron.com
Listed
1991-04-02
Address
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
Phone: (914) 847-7000
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
100
Momentum?
45
Short Sent.?
83
Piotroski F-Score?4/9Mixed
Altman Z-Score?6.29Safe
Confidence?66%Moderate
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?2.83%Low
Short Interest?2.8M
Days to Cover?3.6
Free Float98.3M
Avg Daily Volume764.0K
Settlement Date2026-05-15
Financial Health
Current Ratio?3.57Strong
Quick Ratio?2.96Strong
Cash Ratio?0.58Adequate
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 10 peers + S&P 500
Score
83/100
P/E?
Peers
100
S&P
83
14.2CHEAP▾
P/B?
Peers
80
S&P
74
2.00CHEAP▾
P/S?
Peers
91
S&P
36
4.22FAIR▾
P/FCF?
Peers
100
S&P
73
15.3CHEAP▾
EV/EBITDA?
Peers
63
S&P
50
15.1FAIR▾
EV/Sales?
Peers
91
S&P
44
4.20FAIR▾
Returns & Efficiency
ROE?
Peers
29
S&P
51
14.1%STRONG▾
ROA?
Peers
63
S&P
77
10.8%STRONG▾
Cash Flow & Enterprise
FCF?$4.1B
Enterprise Value?$62.7B
Fundamentals ratios updated end of day
MarketsMoversWatchlist